Article
Utilizing a PTPN22 gene signature to predict response to targeted therapies in rheumatoid arthritis
2019-03-24
Abstract excerpt
Despite the development of several targeted therapies for rheumatoid arthritis (RA), there is still no reliable drug-specific predictor to assist rheumatologists in selecting the most effective targeted therapy for each patient. Recently, a gene signature caused by impaired induction of PTPN22 in anti-CD3 stimulated peripheral blood mononuclear cells (PBMC) was observed in healthy at-risk individuals. However, the...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 77950bf7-f6df-5874-bde4-e0263d03f3b0
- DOI
- 10.1101/586982